349 results match your criteria Expert Review of Pharmacoeconomics & Outcomes Research[Journal]


Review of studies reporting actual prices for medicines.

Expert Rev Pharmacoecon Outcomes Res 2018 Nov 23. Epub 2018 Nov 23.

b WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria .

Background: Medicine purchasing and pricing decisions usually rely on officially published prices. Literature has reported evaluations of publicly stated prices. However, due to the frequent use of confidential price arrangements there are indications for paucity of data on actual medicine prices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2019.1552137DOI Listing
November 2018
3 Reads

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

PLoS One 2018 5;13(10):e0205013. Epub 2018 Oct 5.

Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

The objective of this study was to evaluate current approaches to economic modeling in rheumatoid arthritis (RA) and propose a new conceptual model for evaluation of the cost-effectiveness of RA interventions. We followed recommendations from the International Society of Pharmacoeconomics and Outcomes Research-Society of Medical Decision Making (ISPOR-SMDM) Modeling Good Research Practices Task Force-2. The process involved scoping the decision problem by a working group and drafting a preliminary cost-effectiveness model framework. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205013PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173427PMC
October 2018
2 Reads

Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol.

Trials 2018 Sep 27;19(1):525. Epub 2018 Sep 27.

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada.

Background: There is a widely recognized need for more pragmatic trials that evaluate interventions in real-world settings to inform decision-making by patients, providers, and health system leaders. Increasing availability of electronic health records, centralized research ethics review, and novel trial designs, combined with support and resources from governments worldwide for patient-centered research, have created an unprecedented opportunity to advance the conduct of pragmatic trials, which can ultimately improve patient health and health system outcomes. Such trials raise ethical issues that have not yet been fully addressed, with existing literature concentrating on regulations in specific jurisdictions rather than arguments grounded in ethical principles. Read More

View Article

Download full-text PDF

Source
https://trialsjournal.biomedcentral.com/articles/10.1186/s13
Publisher Site
http://dx.doi.org/10.1186/s13063-018-2895-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161426PMC
September 2018
12 Reads
2.120 Impact Factor

A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.

J Clin Epidemiol 2019 Jan 18;105:50-59. Epub 2018 Sep 18.

LSE Health, Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.

Objective: To identify and assess the methods for estimating comparative clinical effectiveness for novel pharmaceutical products licensed on the basis of nonrandomized controlled trial (non-RCT) data and to evaluate the corresponding National Institute for Health and Care Excellence (NICE) recommendations.

Methods: Our identification strategy was twofold. First, we reviewed all NICE appraisals between 2010 and 2016 and identified technologies where comparative clinical effectiveness estimates were calculated using non-RCT data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jclinepi.2018.09.003DOI Listing
January 2019
6 Reads

Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.

Value Health Reg Issues 2018 Sep 22;16:46-60. Epub 2018 Aug 22.

College of Pharmacy, Qatar University, Doha, Qatar. Electronic address:

Objectives: To review literature characteristics, describe methodological trends, and assess the reporting quality of the economic evaluations of oral anticancer drugs (OACDs).

Methods: The review included comparative economic evaluations of OACDs. The search was conducted via PubMed, Embase, EconLit, and Economic Evaluation Database, and studies till December 2017 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2018.05.003DOI Listing
September 2018
6 Reads

The Future of Precision Medicine: Potential Impacts for Health Technology Assessment.

Pharmacoeconomics 2018 Dec;36(12):1439-1451

York Health Economics Consortium, University of York, York, UK.

Objective: Precision medicine allows healthcare interventions to be tailored to groups of patients based on their disease susceptibility, diagnostic or prognostic information, or treatment response. We analysed what developments are expected in precision medicine over the next decade and considered the implications for health technology assessment (HTA) agencies.

Methods: We performed a pragmatic literature search to account for the large size and wide scope of the precision medicine literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-018-0686-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244622PMC
December 2018
10 Reads

A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease.

Expert Opin Pharmacother 2018 Aug 9;19(11):1245-1259. Epub 2018 Aug 9.

a School of Public Health and Health Systems , University of Waterloo , Waterloo , Ontario , Canada.

Introduction: Alzheimer's disease (AD) results in progressively worsening cognitive decline, leading to loss of functional ability, behavior/mood disturbances, institutionalization, and death. Current pharmaceutical therapies only treat the symptoms of cognitive decline yet can be expensive for payers. Areas covered: The authors undertook a systematic review of economic evaluations of pharmaceutical therapies for AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1499727DOI Listing

Methylnaltrexone bromide for the treatment of opioid-induced constipation.

Expert Opin Pharmacother 2018 Jul 6;19(10):1127-1135. Epub 2018 Jul 6.

c The Institute of Pharmaceutical Sciences (TIPS) , Tehran University of Medical Sciences , Tehran , Iran.

Introduction: The extensive and alarming use of opioids for pain management in patients with chronic pain receiving palliative care is associated with non-tolerable gastrointestinal (GI) adverse effects. Opioid-induced constipation (OIC) is the most common adverse effect impairing patient quality of life (QOL). In addition, OIC is one of the treatment limiting consequences of opioid analgesics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1491549DOI Listing

The economic burden of preventable adverse drug reactions: a systematic review of observational studies.

Expert Opin Drug Saf 2018 Jul 3;17(7):681-695. Epub 2018 Jul 3.

a Unit of Clinical Pharmacology , AOU Policlinico "G. Martino" , Messina , Sicily , Italy.

Introduction: Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide. They are associated with healthcare costs due to hospital admissions or prolonged length of stay, as well as additional interventions. The aim of this study was to conduct a systematic review of observational studies to evaluate the economic impact of preventable ADRs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2018.1491547DOI Listing
July 2018
10 Reads

Therapeutic applications and pharmacoeconomics of microneedle technology.

Expert Rev Pharmacoecon Outcomes Res 2018 Aug 14;18(4):359-369. Epub 2018 Jun 14.

a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutics Sciences , Faculty of Health Sciences, University of the Witwatersrand , Johannesburg , South Africa.

Introduction: Microneedle (MN) arrays contain a backing plate with multiple microscopic projections to puncture the skin and can be used to deliver drug in a minimally invasive way. Advantages of MNs are numerous including administration of large molecules, avoiding first-pass metabolism, ease of administration, lack of pain, site-specific drug targeting, and dose reduction due to increased absorption efficacy. The growth in the transdermal market has been fueled by an increasing number of chronic disease patients and a demand for easy and pain-free drug administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1485100DOI Listing
August 2018
1 Read

Evaluation of the Macy Catheter®: a rectal catheter for rapid medication and fluid administration.

Expert Rev Med Devices 2018 Jun 5;15(6):407-414. Epub 2018 Jun 5.

d Director of Clinical Services , Hospi Corporation , Newark , CA , USA.

Introduction: Health care providers are increasingly challenged to balance cost considerations for devices, drugs, and staffing all while continuing to provide excellent care. Patients in both the post-acute and acute care settings often require fluid and/or medication when their oral route is compromised and vascular access may not be warranted or immediately accessible. The rectum is an underutilized administration point that can be accessed with speed and relative ease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17434440.2018.1481744DOI Listing

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries.

Expert Rev Pharmacoecon Outcomes Res 2018 Aug 30;18(4):403-414. Epub 2018 May 30.

c School of Pharmacy, Faculty of Medical and Health Sciences , The University of Auckland , Auckland , New Zealand.

Background: The importance of pharmacoeconomics and health economics has been augmented. It has the potential to provide evidence to aid in optimal decision-making in the funding of cost-effective medicines and services in Gulf Cooperation Council countries (G.C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1479254DOI Listing

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

Value Health 2018 05 11;21(5):493-500. Epub 2018 Apr 11.

Health Technology Assessment, Erasmus University, Rotterdam, The Netherlands.

Background: Successful development of new treatments for rare diseases (RDs) and their sustainable patient access require overcoming a series of challenges related to research and health technology assessment (HTA). These impediments, which may be unique to RDs or also apply to common diseases but are particularly pertinent in RDs, are diverse and interrelated.

Objective: To develop for the first time a catalog of primary impediments to RD research and HTA, and to describe the cause and effect of individual challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2018.03.004DOI Listing
May 2018
2 Reads

How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review.

Expert Rev Pharmacoecon Outcomes Res 2018 Aug 29;18(4):379-391. Epub 2018 Apr 29.

c Department of Pharmacoeconomics , Medical University of Warsaw , Warsaw , Poland.

Introduction: As budget constraints become more and more visible, there is growing recognition for greater transparency and greater stakeholders' engagement in the pharmaceuticals' pric-ing&reimbursement (P&R) decision making. New frameworks of drugs' value assessments are searched for. Among them, the multi-criteria decision analysis (MCDA) receives more and more attention. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737167.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737167.2018.1467759DOI Listing
August 2018
3 Reads

A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.

Expert Opin Pharmacother 2018 Mar 6;19(4):319-325. Epub 2018 Mar 6.

a Department of Pharmacy , University of Pittsburgh Medical Center St. Margaret Hospital , Pittsburgh , PA , USA.

Introduction: Acute bacterial skin and skin-structure infections (ABSSSI) are common infectious diseases (ID) that often require intravenous (IV) antibiotics. Dalbavancin is a novel lipoglycopeptide antibiotic administered once that is FDA-approved for the treatment of ABSSSI. No literature is available for real-world cost-comparability relative to conventional therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1442439DOI Listing
March 2018
6 Reads

Treatment of early stage chronic hepatitis C virus infection.

Expert Rev Clin Pharmacol 2018 May 9;11(5):519-524. Epub 2018 Mar 9.

b Gastroenterology Unit, Department of Internal Medicine , University of Genoa, IRCCS Ospedale Policlinico San Martino , Genoa , Italy.

Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2018.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2018.1447923DOI Listing
May 2018
10 Reads

Cost-effectiveness thresholds: methods for setting and examples from around the world.

Expert Rev Pharmacoecon Outcomes Res 2018 Jun 27;18(3):277-288. Epub 2018 Feb 27.

a Department of Social Pharmacy, College of Pharmacy , Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , Brazil.

Introduction: Cost-effectiveness thresholds (CETs) are used to judge if an intervention represents sufficient value for money to merit adoption in healthcare systems. The study was motivated by the Brazilian context of HTA, where meetings are being conducted to decide on the definition of a threshold. Areas covered: An electronic search was conducted on Medline (via PubMed), Lilacs (via BVS) and ScienceDirect followed by a complementary search of references of included studies, Google Scholar and conference abstracts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1443810DOI Listing
June 2018
4 Reads

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

Acute Med Surg 2018 01 5;5(1):3-89. Epub 2018 Feb 5.

Department of Emergency and Critical Care Medicine Chiba University Graduate School of Medicine Chiba Japan.

Background And Purpose: The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in February 2017 in Japanese. An English-language version of these guidelines was created based on the contents of the original Japanese-language version.

Methods: Members of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine were selected and organized into 19 committee members and 52 working group members. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ams2.322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797842PMC
January 2018
14 Reads

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

J Intensive Care 2018 2;6. Epub 2018 Feb 2.

15Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Background And Purpose: The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in February 2017 and published in , [2017; Volume 24 (supplement 2)] 10.3918/jsicm.24S0001 and [2017; Volume 28, (supplement 1)] http://onlinelibrary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40560-017-0270-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797365PMC
February 2018
17 Reads

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.

Expert Opin Drug Metab Toxicol 2018 Mar 30;14(3):317-330. Epub 2018 Jan 30.

d International Campus , Tehran University of Medical Sciences , Tehran , Iran.

Introduction: Malignant melanoma (MM) is an aggressive disease with a rapidly rising incidence due to neoplasm of melanocytes. Molecular targeted therapies have demonstrated lower toxicity and improved overall survival versus conventional therapies of MM. The revealing of mutations in the BRAF/MEK/ERK pathway has led to the development of BRAF inhibitors such as vemurafenib and dabrafenib for the treatment of cutaneous MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2018.1432593DOI Listing
March 2018
6 Reads
2.830 Impact Factor

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.

Drug Saf 2018 06;41(6):603-613

Department of Clinical Decision Support, Health Base Foundation, Houten, The Netherlands.

Introduction: The presence of liver cirrhosis can have a major impact on pharmacodynamics and pharmacokinetics, but guidance for prescribing is lacking.

Objective: The aim of this study is to provide an overview of evidence-based recommendations developed for the safe use of drugs in liver cirrhosis.

Methods: Recommendations were based on a systematic literature search combined with expert opinion from a panel of 10 experts. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40264-017-0635-x
Publisher Site
http://dx.doi.org/10.1007/s40264-017-0635-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966501PMC
June 2018
12 Reads

Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015.

Health Econ Policy Law 2018 Jan 8:1-23. Epub 2018 Jan 8.

6Department of Economics,University of Massachusetts,Amherst, MA,USA.

Transparency is recognised to be a key underpinning of the work of health technology assessment (HTA) agencies, yet it has only recently become a subject of systematic inquiry. We contribute to this research field by considering the Polish Agency for Health Technology Assessment (AHTAPol). We situate the AHTAPol in a broader context by comparing it with the National Institute for Health and Care Excellence (NICE) in England. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1744133117000342DOI Listing
January 2018
11 Reads

Secondary patents in the pharmaceutical industry: missing the wood for the trees?

Expert Opin Ther Pat 2018 Mar 7;28(3):241-250. Epub 2018 Jan 7.

a Council of Scientific and Industrial Research-Unit for Research and Development of Information Products (CSIR-URDIP) , India.

Introduction: The critics of the Innovator pharmaceutical industry allege that secondary patents are trivial modifications over the primary patent, which extend its term and delay the entry of the generics in the market place. The protagonists regard secondary patents a result of continuous research and development (R&D), which help them introduce and protect new, differentiated products. Areas covered: The areas covered are Product life cycle management (PLCM), Drug approval process, Orange book (OB) listed patents, US patent data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2018.1424134DOI Listing
March 2018
5 Reads

Investigational opioid antagonists for treating opioid-induced bowel dysfunction.

Expert Opin Investig Drugs 2018 Mar 26;27(3):235-242. Epub 2017 Dec 26.

d Toxicology and Diseases Group, Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran.

Introduction: Opioids have been highlighted for their role in pain relief among cancer and non-cancer patients. Novel agents have been investigated to reduce opioid-induced constipation (OIC) as the main adverse effect that may lead to treatment discontinuation. Development of peripherally acting mu-opioid receptor antagonists (PAMORA) has resulted in a novel approach to preserve the efficacy of pain control along with less OIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2018.1420778DOI Listing
March 2018
3 Reads

The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).

Pharmacoeconomics 2018 Apr;36(4):407-417

Faculty of Economics, University of Rennes 1, CREM-CNRS, 35065, Rennes Cedex, France.

Background: Budget impact analysis (BIA) provides short- and medium-term estimates on changes in budgets and health outcomes resulting from the adoption of new health interventions.

Objective: The purpose of this study is to present the newly developed French National Authority for Health (HAS) guidelines on budget impact analysis as follows: process, literature review, recommendations and comparisons with other guidelines.

Methods: The development process of the HAS guidelines included a literature review (search dates: January 2000 to June 2016), a retrospective investigation of BIA previously submitted to HAS, a public consultation, international expert reviews and approval from the HAS Board and the Economic and Public Health Evaluation Committee of HAS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-017-0602-5DOI Listing

Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.

Expert Rev Pharmacoecon Outcomes Res 2018 Apr 20;18(2):147-160. Epub 2017 Dec 20.

a Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics , CHU Sart-Tilman , Liège , Belgium.

Introduction: The pharmaceutical industry is undergoing major shifts due to changing macro and micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses two completed deals in 2016 above 1bn USD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1417040DOI Listing
April 2018
4 Reads

An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?

Expert Rev Pharmacoecon Outcomes Res 2018 Feb 4;18(1):5-12. Epub 2017 Dec 4.

c Tolley Health Economics , Buxton , Derbyshire , UK.

Introduction: With the introduction of new expensive medicines, traditional pricing schemes based on constructs such as price per pill/vial have been challenged. Potential innovative schemes could be either financial-based or performance-based. Within financial-based schemes the use of price discrimination is an emerging option, which we explore in this assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1411192DOI Listing
February 2018
17 Reads

Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.

Expert Opin Biol Ther 2018 03 29;18(3):309-315. Epub 2017 Nov 29.

b Department of Biomedical and Dental Sciences and Morphofunctional Imaging , University of Messina , Messina , Italy.

Introduction: Since 2006, biosimilars have been available in several countries worldwide, thus allowing for potential savings in pharmaceutical expenditure. However, there have been numerous debates about the interchangeability of biosimilars and reference products based on concerns of immunogenicity by switching between biological products, which may cause lack of effect and toxicity. Areas covered: The authors provide the reader with an overview of the different positions of regulatory authorities on the interchangeability and automatic substitution of biosimilars and reference products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1410134DOI Listing
March 2018
4 Reads

Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.

Expert Rev Pharmacoecon Outcomes Res 2018 Feb 22;18(1):51-69. Epub 2017 Nov 22.

b St Louis College of Pharmacy , Pharmacy Administration , St. Louis , MO , USA.

Introduction: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia. The objective of this study was to systematically review the cost-effectiveness of lipid-lowering agents. Areas covered: Based on Pubmed, Embase, and Cochrane Database of Systematic Reviews, we identified 29 relevant articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1407246DOI Listing
February 2018
24 Reads

Recent developments concerning the application of the Mannich reaction for drug design.

Expert Opin Drug Discov 2018 01 14;13(1):39-49. Epub 2017 Nov 14.

a Organic Chemistry Laboratory , University of Bayreuth , Bayreuth , Germany.

Introduction: The versatile multicomponent Mannich reaction occupies a salient position in organic chemistry and drug design. Sound knowledge of its scope and variations and of the biological activities of Mannich bases is crucial for the development and improvement of drugs for various diseases. Areas covered: The following article provides an overview of the latest developments in the field of drugs based on the Mannich reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1403420DOI Listing
January 2018
13 Reads

Health economic evidence gaps and methodological constraints in low back pain and neck pain: Results of the Research Agenda for Health Economic Evaluation (RAHEE) project.

Best Pract Res Clin Rheumatol 2016 12 5;30(6):981-993. Epub 2017 Oct 5.

Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, MOVE Research Institute Amsterdam, The Netherlands.

Despite the increased interest in economic evaluations, there are difficulties in applying the results of such studies in practice. Therefore, the "Research Agenda for Health Economic Evaluation" (RAHEE) project was initiated, which aimed to improve the use of health economic evidence in practice for the 10 highest burden conditions in the European Union (including low back pain [LBP] and neck pain [NP]). This was done by undertaking literature mapping and convening an Expert Panel meeting, during which the literature mapping results were discussed and evidence gaps and methodological constraints were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2017.09.001DOI Listing
December 2016
6 Reads

Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.

J Antibiot (Tokyo) 2017 Dec 1;70(12):1087-1096. Epub 2017 Nov 1.

Department of Health Policy, London School of Economics and Political Science, London, UK.

Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ja.2017.124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746591PMC
December 2017
6 Reads

The cost-effectiveness of therapies to treat alcohol use disorders.

Authors:
J Rehm C Barbosa

Expert Rev Pharmacoecon Outcomes Res 2018 Feb 20;18(1):43-49. Epub 2017 Oct 20.

g Behavioral Health and Criminal Justice Division , RTI International , Chicago , IL , USA.

Introduction: Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. Areas covered: We searched the literature for the cost-effectiveness of alcohol interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1392241DOI Listing
February 2018
2 Reads

Deuterated drugs; updates and obviousness analysis.

Authors:
Graham S Timmins

Expert Opin Ther Pat 2017 Dec 14;27(12):1353-1361. Epub 2017 Sep 14.

a College of Pharmacy , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.

Introduction: The pharmacokinetics and/or toxicity of many known drugs can be modified by selective deuteration, an area of significant commercial interest and scientific and regulatory progress. Areas covered: This review firstly discusses recent developments in deuterated drugs including the FDA approval of deutetrabenazine. Secondly, it discusses 35 U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1378350DOI Listing
December 2017
10 Reads

Social and economic value of Portuguese community pharmacies in health care.

BMC Health Serv Res 2017 Aug 29;17(1):606. Epub 2017 Aug 29.

Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.

Background: Community pharmacies are major contributors to health care systems across the world. Several studies have been conducted to evaluate community pharmacies services in health care. The purpose of this study was to estimate the social and economic benefits of current and potential future community pharmacies services provided by pharmacists in health care in Portugal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12913-017-2525-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576248PMC

Economic evaluation of pharmacist-led medication reviews in residential aged care facilities.

Expert Rev Pharmacoecon Outcomes Res 2017 Oct 1;17(5):431-439. Epub 2017 Sep 1.

b Department of Pharmacy , University of Huddersfield , Huddersfield , UK.

Introduction: Medication reviews is a widely accepted approach known to have a substantial impact on patients' pharmacotherapy and safety. Numerous options to optimise pharmacotherapy in older people have been reported in literature and they include medication reviews, computerised decision support systems, management teams, and educational approaches. Pharmacist-led medication reviews are increasingly being conducted, aimed at attaining patient safety and medication optimisation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1370376DOI Listing
October 2017
2 Reads

New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.

Health Policy 2017 Aug 23;121(8):836-841. Epub 2017 Jun 23.

Department of Healthcare Economics and Health policy, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 1130033, Japan.

Economic evaluation is used for decision-making processes in healthcare technologies in many developed countries. In Japan, no health economic data have been requested for drugs, medical devices, and interventions till date. However, economic evaluation is gradually gaining importance, and a trial implementation of the cost-effectiveness evaluation of drugs and medical devices has begun. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healthpol.2017.06.001DOI Listing
August 2017
7 Reads

Micro factors bringing the pharmaceutical industry to a seismic shaking a qualitative research.

Expert Rev Pharmacoecon Outcomes Res 2017 Jun 14;17(3):267-274. Epub 2017 Jul 14.

a Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics , CHU Sart-Tilman , Liège , Belgium.

Introduction: Due to changing macro and micro factors, expiring patents and falling net income, pharmaceutical companies need to rethink their vertical business model. The trend shows cross-sectorial partnerships and consolidation to remain and compete on the market. Areas covered: Quantitative research interviewing a target group of 25 key executives from small, mid and large global pharmaceutical companies rounded with qualitative literature research completing the analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1351877DOI Listing
June 2017
5 Reads

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.

Pharmacoeconomics 2017 Oct;35(10):1047-1062

Outcomes and Evidence, Global Health and Value, Pfizer Inc., New York, NY, USA.

Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction of biosimilars is of interest. Budget impact analysis (BIA) is a commonly used methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-017-0529-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606961PMC
October 2017
17 Reads

Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.

Expert Opin Biol Ther 2017 08 26;17(8):915-926. Epub 2017 Jun 26.

a Syreon Research Institute , Budapest , Hungary.

Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well-accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well-designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2017.1341486DOI Listing
August 2017
70 Reads

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.

Front Pharmacol 2017 8;8:288. Epub 2017 Jun 8.

Croatian Agency for Medicinal Products and Medical DevicesZagreb, Croatia.

The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countries. A questionnaire-based survey was conducted between November 2016 and January 2017 among experts from the following CEE countries: Bulgaria, Czech Republic, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania. The requirements for the pricing and reimbursement of biosimilars were reviewed for each country. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2017.00288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463127PMC
June 2017
20 Reads

New perspectives for chronic pain treatment: a patent review (2010-2016).

Expert Opin Ther Pat 2017 Jul 3;27(7):787-796. Epub 2017 Mar 3.

b Department of Health Education , Federal University of Sergipe , Sergipe , Brazil.

Introduction: Chronic pain is a major problem of public health worldwide and is responsible for the increase in health costs. The therapeutic options available in the market for the treatment of chronic pain are often rather ineffective due to; the high number of adverse reactions, tolerance and dependence, reducing the quality of life, pharmacotherapy adherence and functional capacity. Hence, several studies have been conducted in the search for new treatment alternatives for chronic pain syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1297425DOI Listing
July 2017
10 Reads

Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.

J Manag Care Spec Pharm 2017 Jun 2;23(6):621-627. Epub 2017 Feb 2.

1 National Pharmaceutical Council, Washington, DC.

Background: Tiered formularies, in which patients pay copays or coinsurance out-of-pocket (OOP), are used to manage costs and encourage more efficient health care resource use. Formulary tiers are typically based on the cost of treatment rather than the medical appropriateness for the patient. Cost sharing may have unintended consequences on treatment adherence and health outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2017.16009DOI Listing
June 2017
18 Reads

Direct and indirect cost of managing alzheimer's disease and related dementias in the United States.

Expert Rev Pharmacoecon Outcomes Res 2017 Apr;17(2):189-202

b School of Public Health, Department of Epidemiology , West Virginia University, Morgantown, USA.

Introduction: Care of individuals with Alzheimer's Disease and Related Dementias (ADRD) poses special challenges. As the disease progresses, individuals with ADRD require increasing levels of medical care, caregiver support, and long-term care which can lead to substantial economic burden. Areas covered: In this expert review, we synthesized findings from studies of costs of ADRD in the United States that were published between January 2006 and February 2017, highlighted major sources of variation in costs, identified knowledge gaps and briefly outlined directions for future research and implications for policy and program planning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1313118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494694PMC
April 2017
8 Reads

The antibiotic pipeline: reviving research and development and speeding drugs to market.

Expert Rev Anti Infect Ther 2017 05 29;15(5):425-433. Epub 2017 Mar 29.

a Medical Affairs Strategic Solutions, LLC , Atlanta , GA , USA.

Introduction: The combination of growing antimicrobial resistance with a dry pipeline has resulted in infections that can no longer be treated. Specific reasons have led to companies' exit from the antibacterial space, however recent incentives are spurring interest to reinvigorate the pipeline. Areas covered: This article summarizes the available information on the discovery, developmental, and regulatory challenges in antibacterial development that have led to disinterest in the space, as well as ongoing incentives such as public-private partnerships and streamlined pathways to mend these challenges and bring new antibiotics to patients in need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2017.1308251DOI Listing
May 2017
1 Read

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.

Eur J Health Econ 2018 Jan 16;19(1):123-152. Epub 2017 Mar 16.

Department of Social Policy and Medical Technology Research Group, LSE Health, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.

Background: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value.

Objective: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment.

Methods: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) 'Responsibilities and structure of HTA agencies'; (2) 'Evidence and evaluation criteria considered in HTAs'; (3) 'Methods and techniques applied in HTAs'; and (4) 'Outcomes and implementation of HTAs'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10198-017-0871-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773640PMC
January 2018
12 Reads

The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.

Expert Rev Pharmacoecon Outcomes Res 2017 Apr 22;17(2):133-140. Epub 2017 Mar 22.

b Health Economics and Outcomes Research - US Medical , Bristol-Myers Squibb Company , Princeton , NJ , USA.

Introduction: Since the introduction of tyrosine kinase inhibitors (TKIs), the treatment of patients with chronic myelogenous leukemia (CML) has resulted in significant improvement in patient survival but at a higher pharmaceutical cost to payers. The recent introduction of generic imatinib presents an opportunity to lower pharmacy costs within a population that is growing due to improved survival. Recent literature has focused on the likely benefits to payers of step therapy through generic imatinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1305892DOI Listing
April 2017
4 Reads

The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

Expert Rev Pharmacoecon Outcomes Res 2017 Aug 25;17(4):421-429. Epub 2017 Jan 25.

b Department of Pharmaceutical and Pharmacological Sciences , KU Leuven , Leuven , Belgium.

Background: Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from a too narrow perspective' and (iv) 'The lack of well-described & standardized interventions'. This study aims to determine how healthcare providers and social workers experience and deal with these hurdles in practice and what solutions or new insights they would suggest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1282316DOI Listing

Healthcare burden of depression in adults with arthritis.

Expert Rev Pharmacoecon Outcomes Res 2017 Feb 20;17(1):53-65. Epub 2017 Jan 20.

a Department of Pharmaceutical Systems and Policy , School of Pharmacy, West Virginia University , Morgantown , WV , USA.

Introduction: Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their families, payers, healthcare systems, and society as a whole. Areas covered: The primary objective of this review is to summarize, identify knowledge gaps and discuss the challenges in estimating the healthcare burden of depression among individuals with arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1281744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512931PMC
February 2017
2 Reads

National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.

Expert Rev Pharmacoecon Outcomes Res 2017 Aug 3;17(4):401-409. Epub 2017 Jan 3.

a School of Pharmacy , Sungkyunkwan University , Suwon , South Korea.

Background: Since the positive-list system was introduced, concerns have been raised over restricting access to new cancer drugs in Korea. Policy changes in the decision-making process, such as risk-sharing agreement and the waiver of pharmacoeconomic data submission, were implemented to improve access to oncology medicines, and other factors are also involved in the reimbursement for cancer drugs. The aim of this study is to investigate the reimbursement listing determinants of new cancer drugs in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2017.1276828DOI Listing
August 2017
2 Reads